14 results about "Cannabinoid receptor" patented technology

The present application relates to a kind of annelated derivative and its preparation method and use, specifically provide the compound or its pharmaceutically acceptable salt, stereoisomer as selective agonist of cannabinoid receptor CB2, wherein the compound has the structure of formula (I).

Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and / or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

Heteroaromatic compounds are provided which are allosteric modulators of the cannabinoid receptors and which are useful for the treatment of glaucoma, pain, neuropathic pain, post-traumatic stress disorder (PTSD), and neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases where cannabinoid receptors are involved.

The present application provides a radiolabeled compound targeting cannabinoid receptor type 1 with radionuclide 18F. The present application also provides a method for preparing the compound and its use as a positron emission tomography (PET) imaging agent.

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None

The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH).

The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and obesity, are described.

The present specification provides isolated, engineered, non-naturally occurring CB1-binding proteins, comprising anti-CB1 antibodies or antigen-binding fragments thereof. The CB1-binding proteins have uses in the treatment and diagnosis of CB1-mediated conditions, diseases, and disorders.

To provide isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof, wherein the CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.SOLUTION: The present invention provides an isolated antibody or an antigen-binding fragment thereof that binds to the human cannabinoid receptor type 1 (CB1), including CDRs of the variable heavy (VH) domain sequence and CDRs of the variable light (VL) domain sequence.SELECTED DRAWING: None

The present invention relates to radiolabeled cannabinoid receptor 2 ligands. In particular, the present invention relates to compounds of formula (I), wherein R 1 , R 2 and R 3 are as defined in the description and in the claims. The compounds of formula (I) can be used as radiolabeled ligands.

The present application relates to a substituted diphenyl derivative, a preparation method thereof and a pharmaceutical composition containing the derivative in medical application. Specifically, the present application relates to a substituted diphenyl derivative shown in general formula (I), a preparation method thereof and a pharmaceutically acceptable salt thereof, and the use thereof in treating or preventing diseases and disorders related to cannabinoid CB1 receptor, wherein the definitions of the substituents in general formula (I) are the same as those in the specification.

The present invention provides compounds useful as modulators of cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein; compositions comprising the compounds; methods of making the compounds; and methods of using the compounds. (I)